Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
London Pharmaceuticals And Research Corporation is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters is decentralized, involving 4 distinct examiners across 4 distinct art units. This means that every one of the 4 pending office actions is being handled by a different examiner in a different art unit, requiring a broad range of prosecution strategies.
The busiest examiner identified is IANNUZO, NATALIE NMN, who is responsible for 1 busiest examiner pending office action. Given that there are 4 distinct examiners for the 4 pending office actions, the workload is evenly distributed across the 4 distinct art units. This lack of concentration suggests that the Biotechnology & Pharmaceuticals filings cover a diverse range of sub-technologies or applications.
Practitioners must account for the specific practices of 4 distinct art units when responding to the 4 pending office actions. Because each of the 4 distinct examiners, including IANNUZO, NATALIE NMN, has only 1 busiest examiner pending office action, there is no single examiner with a dominant influence over the portfolio. The 4 pending office actions represent a fragmented but balanced prosecution landscape.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 1 | 12.5% | +71.4% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| ISMAIL, REHANA | 1 | 75.8% | +34.8% |
| SHIAO, YIH-HORNG | 1 | 72.5% | +75.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007982 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | SHIAO, YIH-HORNG | 23d overdue |
| 18572696 | CANNABINOID-CONTAINING FORMULA FOR SKIN CARE | IANNUZO, NATALIE NMN | — |
| 18560206 | PSILOCYBIN AND PSILOCIN CONJUGATES FOR TREATMENT OF MENTAL ILLNESSES | DEKARSKE, MADELINE MCGUIRE | — |
| 18007935 | RIGID CANNABIDIOL ANALOGUES AS POTENT MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF | ISMAIL, REHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007982 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | SHIAO, YIH-HORNG | 23d overdue |
| 18572696 | CANNABINOID-CONTAINING FORMULA FOR SKIN CARE | IANNUZO, NATALIE NMN | — |
| 18007935 | RIGID CANNABIDIOL ANALOGUES AS POTENT MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF | ISMAIL, REHANA | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1622 | 1 |
| 1625 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572696 | CANNABINOID-CONTAINING FORMULA FOR SKIN CARE | IANNUZO, NATALIE NMN | 1653 | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18560206 | PSILOCYBIN AND PSILOCIN CONJUGATES FOR TREATMENT OF MENTAL ILLNESSES | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18007935 | RIGID CANNABIDIOL ANALOGUES AS POTENT MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF | ISMAIL, REHANA | 1625 | §101§102§112 | Non-Final OA | — | Pending | Dec 02, 2022 |
| 18007982 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | SHIAO, YIH-HORNG | 1691 | §102§103§112 | Non-Final OA | 23d overdue | Pending | Dec 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial